|
1
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Terry MB, Gaudet MM and Gammon MD: The
epidemiology of gastric cancer. Semin Radiat Oncol. 12:111–127.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang L: Incidence and mortality of gastric
cancer in China. World J Gastroenterol. 12:17–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoo CH, Noh SH, Shin DW, Choi SH and Min
JS: Recurrence following curative resection for gastric carcinoma.
Br J Surg. 87:236–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qin X, Xu H, Gong W and Deng W: The tumor
cytosol miRNAs, fluid miRNAs, and exosome miRNAs in Lung Cancer.
Front Oncol. 4:3572015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rigoutsos I: New tricks for animal
microRNAS: Targeting of amino acid coding regions at conserved and
nonconserved sites. Cancer Res. 69:3245–3248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang H, Li M, Zhang R, Wang Y, Zang W, Ma
Y, Zhao G and Zhang G: Effect of miR-335 upregulation on the
apoptosis and invasion of lung cancer cell A549 and H1299. Tumour
Biol. 34:3101–3109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He H, Di Y, Liang M, Yang F, Yao L, Hao S,
Li J, Jiang Y, Jin C and Fu D: The microRNA-218 and ROBO-1
signaling axis correlates with the lymphatic metastasis of
pancreatic cancer. Oncol Rep. 30:651–658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu YY, Wu HJ, Ma HD, Xu LP, Huo Y and Yin
LR: MicroRNA-503 suppresses proliferation and cell cycle
progression of endometrioid endometrial cancer via negatively
regulating cyclin D1. FEBS J. 280:3768–3779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao S, Yao DS, Chen JY and Ding N:
Aberrant expression of miR-20a and miR-203 in cervical cancer.
Asian Pac J Cancer Prev. 14:2289–2293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang H, Zhang G, Wu JH and Jiang CP:
Diverse roles of miR-29 in cancer. Oncol Rep. 31:1509–1516. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sengupta S, den Boon JA, Chen IH, Newton
MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B and
Ahlquist P: MicroRNA 29c is down-regulated in nasopharyngeal
carcinomas, up-regulating mRNAs encoding extracellular matrix
proteins. Proc Natl Acad Sci USA. 105:5874–5878. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong J, Li J, Wang Y, Liu C, Jia H, Jiang
C, Wang Y, Luo M, Zhao H, Dong L, et al: Characterization of
microRNA-29 family expression and investigation of their
mechanistic roles in gastric cancer. Carcinogenesis. 35:497–506.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oliveira LH, Schiavinato JL, Fráguas MS,
Lucena-Araujo AR, Haddad R, Araújo AG, Dalmazzo LF, Rego EM, Covas
DT, Zago MA and Panepucci RA: Potential roles of microRNA-29a in
the molecular pathophysiology of T-cell acute lymphoblastic
leukemia. Cancer Sci. 106:1264–1277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH,
Kim MG, Chang YG, Shen Q, Kim SJ, Park WS, et al: MicroRNA-29c
functions as a tumor suppressor by direct targeting oncogenic SIRT1
in hepatocellular carcinoma. Oncogene. 33:2557–2567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu DW, Hsu NY, Wang YC, Lee MC, Cheng YW,
Chen CY and Lee H: c-Myc suppresses microRNA-29b to promote tumor
aggressiveness and poor outcomes in non-small cell lung cancer by
targeting FHIT. Oncogene. 34:2072–2082. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inoue A, Yamamoto H, Uemura M, Nishimura
J, Hata T, Takemasa I, Ikenaga M, Ikeda M, Murata K, Mizushima T,
et al: MicroRNA-29b is a novel prognostic marker in colorectal
cancer. Ann Surg Oncol. 22 Suppl 3:S1410–S1418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi Y, Huang Y, Pang L, Gu W, Wang N, Hu J,
Cui X, Zhang J, Zhao J, Liu C, et al: Prognostic value of the
MicroRNA-29 family in multiple human cancers: A meta-analysis and
systematic review. Clin Exp Pharmacol Physiol. 44:441–454. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Q, Costinean S, Croce CM, Brasier AR,
Merwat S, Larson SA, Basra S and Verne GN: MicroRNA 29 targets
nuclear factor-κB-repressing factor and Claudin 1 to increase
intestinal permeability. Gastroenterology. 148:158–169.e8. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishikawa R, Chiyomaru T, Enokida H,
Inoguchi S, Ishihara T, Matsushita R, Goto Y, Fukumoto I, Nakagawa
M and Seki N: Tumour-suppressive microRNA-29s directly regulate
LOXL2 expression and inhibit cancer cell migration and invasion in
renal cell carcinoma. FEBS Lett. 589:2136–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mizuno K, Seki N, Mataki H, Matsushita R,
Kamikawaji K, Kumamoto T, Takagi K, Goto Y, Nishikawa R, Kato M, et
al: Tumor-suppressive microRNA-29 family inhibits cancer cell
migration and invasion directly targeting LOXL2 in lung squamous
cell carcinoma. Int J Oncol. 48:450–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y,
Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis,
tumorigenicity, and prognosis of hepatocellular carcinoma.
Hepatology. 51:836–845. 2010.PubMed/NCBI
|
|
24
|
Xu XD, Wu XH, Fan YR, Tan B, Quan Z and
Luo CL: Exosome-derived microRNA-29c induces apoptosis of BIU-87
cells by down regulating BCL-2 and MCL-1. Asian Pac J Cancer Prev.
15:3471–3476. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu PN, Yan MD, Lai HC, Huang RL, Chou YC,
Lin WC, Yeh LT and Lin YW: Downregulation of miR-29 contributes to
cisplatin resistance of ovarian cancer cells. Int J Cancer.
134:542–551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rostas JW III, Pruitt HC, Metge BJ, Mitra
A, Bailey SK, Bae S, Singh KP, Devine DJ, Dyess DL, Richards WO, et
al: microRNA-29 negatively regulates EMT regulator N-myc interactor
in breast cancer. Mol Cancer. 13:2002014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui H, Wang L, Gong P, Zhao C, Zhang S,
Zhang K, Zhou R, Zhao Z and Fan H: Deregulation between miR-29b/c
and DNMT3A is associated with epigenetic silencing of the CDH1
gene, affecting cell migration and invasion in gastric cancer. PLoS
One. 10:e01239262015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Liu C, Luo M, Zhang Z, Gong J, Li
J, You L, Dong L, Su R, Lin H, et al: Chemotherapy-induced
miRNA-29c/Catenin-δ signaling suppresses metastasis in gastric
cancer. Cancer Res. 75:1332–1344. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bai F, Guo X, Yang L, Wang J, Shi Y, Zhang
F, Zhai H, Lu Y, Xie H, Wu K and Fan D: Establishment and
characterization of a high metastatic potential in the peritoneum
for human gastric cancer by orthotopic tumor cell implantation. Dig
Dis Sci. 52:1571–1578. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xin R, Bai F, Feng Y, Jiu M, Liu X, Bai F,
Nie Y and Fan D: MicroRNA-214 promotes peritoneal metastasis
through regulating PTEN negatively in gastric cancer. Clin Res
Hepatol Gastroenterol. 40:748–754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
You Y, Yang W, Wang Z, Zhu H, Li H, Lin C
and Ran Y: Promoter hypermethylation contributes to the frequent
suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Cell Oncol. 36:323–331. 2013. View Article : Google Scholar
|
|
32
|
You Y, Yang W, Qin X, Wang F, Li H, Lin C,
Li W, Gu C, Zhang Y and Ran Y: ECRG4 acts as a tumor suppressor and
as a determinant of chemotherapy resistance in human nasopharyngeal
carcinoma. Cell Oncol (Dordr). 38:205–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin C, Xin S, Qin X, Li H, Lin L and You
Y: Zoledronic acid suppresses metastasis of esophageal squamous
cell carcinoma cells through upregulating the tight junction
protein occludin. Cytotechnology. 68:1233–1241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Adamia S, Maxwell CA and Pilarski LM:
Hyaluronan and hyaluronan synthases: Potential therapeutic targets
incancer. Curr Drug Targets Cardiovasc Haematol Disord. 5:3–14.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zheng XL, Wang FS and Ling PX: Research
status of hyaluronan synthases. Pharmaceutical Biotechnol.
11:413–416. 2004.
|
|
36
|
Bullard KM, Kim HR, Wheeler MA, Wilson CM,
Neudauer CL, Simpson MA and McCarthy JB: Hyaluronan synthase-3 is
upregulated in metastatic colon carcinoma cells and manipulation of
expression alters matrix retention and cellular growth. Int J
Cancer. 107:739–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Simpson MA, Reiland J, Burger SR, Furcht
LT, Spicer AP, Oegema TR Jr and McCarthy JB: Hyaluronan synthase
elevation in metastatic prostate carcinoma cells correlates with
hyaluronan surface retention, a prerequisite for rapid adhesion to
bone marrow endothelial cells. J Biol Chem. 276:17949–17957. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kuo YZ, Fang WY, Huang CC, Tsai ST, Wang
YC, Yang CL and Wu LW: Hyaluronan synthase 3 mediated oncogenic
action through forming inter-regulation loop with tumor necrosis
factor alpha in oral cancer. Oncotarget. 8:15563–15583. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Auvinen P, Rilla K, Tumelius R, Tammi M,
Sironen R, Soini Y, Kosma VM, Mannermaa A, Viikari J and Tammi R:
Hyaluronan synthases (HAS1-3) in stromal and malignant cells
correlate with breast cancer grade and predict patient survival.
Breast Cancer Res Treat. 143:277–286. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu N, Gao F, Han Z, Xu X, Underhill CB
and Zhang L: Hyaluronan synthase 3 overexpression promotes the
growth of TSU prostate cancer cells. Cancer Res. 61:5207–5214.
2001.PubMed/NCBI
|
|
41
|
Takabe P, Bart G, Ropponen A, Rilla K,
Tammi M, Tammi R and Pasonen-Seppänen S: Hyaluronan synthase 3
(HAS3) overexpression downregulates MV3 melanoma cell
proliferation, migration and adhesion. Exp Cell Res. 337:1–15.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Teng BP, Heffler MD, Lai EC, Zhao YL,
LeVea CM, Golubovskaya VM and Bullarddunn KM: Inhibition of
hyaluronan synthase-3 decreases subcutaneous colon cancer growth by
increasing apoptosis. Anticancer Agents Med Chem. 11:620–628. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang IW, Liang PI, Li CC, Wu WJ, Huang
CN, Lin VC, Hsu CT, He HL, Wu TF, Hung CH and Li CF: HAS3
underexpression as an indicator of poor prognosis in patients with
urothelial carcinoma of the upper urinary tract and urinary
bladder. Tumour Biol. 36:5441–5450. 2015. View Article : Google Scholar : PubMed/NCBI
|
